77556-27-5

Usage

Uses

Used in Pharmaceutical Industry:
2-(4-Bromo-1H-pyrazol-1-yl)pyridine is used as an intermediate compound for the synthesis of various pharmaceutical products. Its unique structure contributes to the development of new drugs and medicines, enhancing their efficacy and therapeutic potential.
Used in Organic Chemistry Research:
2-(4-Bromo-1H-pyrazol-1-yl)pyridine is used as a reagent in organic chemistry research, facilitating the synthesis of complex organic molecules. Its versatility in reactions makes it a valuable tool for chemists in the development of novel compounds and materials.
Used in Material Science:
2-(4-Bromo-1H-pyrazol-1-yl)pyridine is used as a building block in the creation of new materials with specific properties. Its incorporation into the molecular structure of these materials can lead to enhanced performance in various applications, such as electronics, coatings, and adhesives.
Safety Precautions:
While handling 2-(4-Bromo-1H-pyrazol-1-yl)pyridine, it is essential to take necessary safety precautions as its health effects are not entirely known. It is recommended to store the compound in a cool and dry place with proper ventilation, away from heat or ignition sources to prevent any potential hazards.

InChI:InChI=1/C8H6BrN3/c9-7-5-11-12(6-7)8-3-1-2-4-10-8/h1-6H

Upstream product

• 25700-11-2 2-(pyrazol-1-yl)pyridine 
• 5029-67-4 2-iodopyridine 
• 2075-45-8 4-bromo-1H-pyrazole 
• 4930-98-7 pyrid-2-ylhydrazine 

Downstream Products

• 1373616-12-6 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)pyridine 
• 77556-30-0 2-(4-bromopyrazol-1-yl)-5-nitropyridine 
• 76211-96-6 5-Nitro-2-(4-nitro-pyrazol-1-yl)-pyridine 

Relevant academic research and scientific papers

PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE

The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (I), and sub-formulas thereof: or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for treatment of diseases including heart (e.g. ischemic heart disease, congestive heart failure, and valvular heart disease), lung (e.g., lung inflammation, pneumonia, acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), respiratory (e.g., respiratory infection, acute respiratory distress syndrome), liver (e.g. acute liver failure and liver fibrosis and cirrhosis), and kidney (e.g. acute kidney injury and chronic kidney disease) disease, inflammatory bowel disease (IBD), ischemic reperfusion injury (e.g., stroke), and retinopathy of prematurity (ROP).

Predictable site-selective functionalization: Promoter group assistedpara-halogenation ofN-substituted(hetero)aromatics under metal-free condition

Herein, regioselectivepara-C-H halogenation ofN-pyrimidyl (hetero)aromatics through SEAr (electrophilic aromatic substitution) type reaction is disclosed. SEAr type reaction has been utilized for the C5-bromination of indolines (para-selective) withN-bromosuccinimide under metal and additive-free conditions in good to excellent yields. The developed methodology is also applicable for iodination and challenging chlorination. The pyrimidyl group is identified as a reactivity tuner that also controls the regioselectivity. The present method is also applicable for selective halogenation of aniline, pyridine, indole, oxindole, pyrazole, tetrahydroquinoline, isoquinoline, and carbazole. DFT studies such as Fukui nucleophilicity and natural charge maps also support the observedp-selectivity. Post-functionalization of the title compound into the corresponding arylated, olefinated, and dihalogenated products is achieved in a one-pot, two-step fashion. Late-stage C-H bromination was also executed on drug/natural molecules (harmine, etoricoxib, clonidine, and chlorzoxazone) to demonstrate the applicability of the developed protocol.

Discovery of a 5 H-benzo[4,5]cyclohepta[1,2-b ]pyridin-5-one (MK-2461) inhibitor of c-Met kinase for the treatment of cancer

c-Met is a transmembrane tyrosine kinase that mediates activation of several signaling pathways implicated in aggressive cancer phenotypes. In recent years, research into this area has highlighted c-Met as an attractive cancer drug target, triggering a number of approaches to disrupt aberrant c-Met signaling. Screening efforts identified a unique class of 5H-benzo[4,5] cyclohepta[1,2-b]pyridin-5-one kinase inhibitors, exemplified by 1. Subsequent SAR studies led to the development of 81 (MK-2461), a potent inhibitor of c-Met that was efficacious in preclinical animal models of tumor suppression. In addition, biochemical studies and X-ray analysis have revealed that this unique class of kinase inhibitors binds preferentially to the activated (phosphorylated) form of the kinase. This report details the development of 81 and provides a description of its unique biochemical properties.

Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity

The highly potent, selective, and brain-penetrant metabotropic glutamate subtype 5 (mGlu5) receptor antagonists 3-(5-pyridin-2-yl-2H-tetrazol-2-yl) benzonitrile (47) and 3-fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile (48) are reported. Compound 47 is active in the rat fear-potentiated startle (FPS) model of anxiety with ED50 = 5.4 mg/kg (po) when dosed acutely. In this model the anxiolytic effects of 47 rapidly tolerate on repeated dosing.

Hetarylyrazoles. II. Reactions of Pyrazol-1'-ylpyridines

Pyrazol-1'-ylpyridines undergo electrophilic substitution reactions (bromination, chlorination and nitration) preferentially in the pyrazole ring.There is some evidence of the mutual influence of the pyrazole and the pyridine ring on the reactivity of the